These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 15883754)
1. Erythropoietin just before reperfusion reduces both lethal arrhythmias and infarct size via the phosphatidylinositol-3 kinase-dependent pathway in canine hearts. Hirata A; Minamino T; Asanuma H; Sanada S; Fujita M; Tsukamoto O; Wakeno M; Myoishi M; Okada K; Koyama H; Komamura K; Takashima S; Shinozaki Y; Mori H; Tomoike H; Hori M; Kitakaze M Cardiovasc Drugs Ther; 2005 Jan; 19(1):33-40. PubMed ID: 15883754 [TBL] [Abstract][Full Text] [Related]
3. Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling. Ghaboura N; Tamareille S; Ducluzeau PH; Grimaud L; Loufrani L; Croué A; Tourmen Y; Henrion D; Furber A; Prunier F Basic Res Cardiol; 2011 Jan; 106(1):147-62. PubMed ID: 20981553 [TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Takahama H; Minamino T; Hirata A; Ogai A; Asanuma H; Fujita M; Wakeno M; Tsukamoto O; Okada K; Komamura K; Takashima S; Shinozaki Y; Mori H; Mochizuki N; Kitakaze M Cardiovasc Drugs Ther; 2006 Jun; 20(3):159-65. PubMed ID: 16775664 [TBL] [Abstract][Full Text] [Related]
5. Rho kinase activation plays a major role as a mediator of irreversible injury in reperfused myocardium. Hamid SA; Bower HS; Baxter GF Am J Physiol Heart Circ Physiol; 2007 Jun; 292(6):H2598-606. PubMed ID: 17220176 [TBL] [Abstract][Full Text] [Related]
6. Erythropoietin (EPO) affords more potent cardioprotection by activation of distinct signaling to mitochondrial kinases compared with carbamylated EPO. Sato T; Tanno M; Miki T; Yano T; Sato T; Shimamoto K; Miura T Cardiovasc Drugs Ther; 2010 Dec; 24(5-6):401-8. PubMed ID: 20953685 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. Hanlon PR; Fu P; Wright GL; Steenbergen C; Arcasoy MO; Murphy E FASEB J; 2005 Aug; 19(10):1323-5. PubMed ID: 15946993 [TBL] [Abstract][Full Text] [Related]
8. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808 [TBL] [Abstract][Full Text] [Related]
9. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion. Kobayashi H; Miura T; Ishida H; Miki T; Tanno M; Yano T; Sato T; Hotta H; Shimamoto K Clin Exp Pharmacol Physiol; 2008 Jul; 35(7):812-9. PubMed ID: 18346168 [TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone-induced myocardial protection against ischaemia-reperfusion injury is mediated via a phosphatidylinositol 3-kinase/Akt-dependent pathway. Zhang XJ; Xiong ZB; Tang AL; Ma H; Ma YD; Wu JG; Dong YG Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):156-61. PubMed ID: 19566839 [TBL] [Abstract][Full Text] [Related]
11. Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms. Baker JE; Kozik D; Hsu AK; Fu X; Tweddell JS; Gross GJ J Cardiovasc Pharmacol; 2007 Jun; 49(6):337-45. PubMed ID: 17577097 [TBL] [Abstract][Full Text] [Related]